company background image
002390 logo

Guizhou Xinbang Pharmaceutical SZSE:002390 Stock Report

Last Price

CN¥4.35

Market Cap

CN¥8.3b

7D

0.9%

1Y

-6.9%

Updated

16 Dec, 2024

Data

Company Financials

Guizhou Xinbang Pharmaceutical Co., Ltd.

SZSE:002390 Stock Report

Market Cap: CN¥8.3b

002390 Stock Overview

Researches, develops, manufactures, and sells Chinese herbal medicines and other pharmaceutical products in China and internationally. More details

002390 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends4/6

Risk Analysis


My Notes

Capture your thoughts, links and company narrative

Guizhou Xinbang Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Guizhou Xinbang Pharmaceutical
Historical stock prices
Current Share PriceCN¥4.35
52 Week HighCN¥4.74
52 Week LowCN¥2.86
Beta0.52
1 Month Change21.51%
3 Month Change46.96%
1 Year Change-6.85%
3 Year Change-35.46%
5 Year Change-17.30%
Change since IPO-17.33%

Recent News & Updates

Here's Why Guizhou Xinbang Pharmaceutical (SZSE:002390) Can Manage Its Debt Responsibly

Dec 16
Here's Why Guizhou Xinbang Pharmaceutical (SZSE:002390) Can Manage Its Debt Responsibly

There's No Escaping Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Muted Earnings

Sep 26
There's No Escaping Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Muted Earnings

Recent updates

Here's Why Guizhou Xinbang Pharmaceutical (SZSE:002390) Can Manage Its Debt Responsibly

Dec 16
Here's Why Guizhou Xinbang Pharmaceutical (SZSE:002390) Can Manage Its Debt Responsibly

There's No Escaping Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Muted Earnings

Sep 26
There's No Escaping Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Muted Earnings

Investors Aren't Buying Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Earnings

Jun 26
Investors Aren't Buying Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Earnings

These 4 Measures Indicate That Guizhou Xinbang Pharmaceutical (SZSE:002390) Is Using Debt Safely

May 24
These 4 Measures Indicate That Guizhou Xinbang Pharmaceutical (SZSE:002390) Is Using Debt Safely

Shareholder Returns

002390CN PharmaceuticalsCN Market
7D0.9%-0.9%-0.06%
1Y-6.9%-2.7%11.1%

Return vs Industry: 002390 underperformed the CN Pharmaceuticals industry which returned -2.7% over the past year.

Return vs Market: 002390 underperformed the CN Market which returned 11.1% over the past year.

Price Volatility

Is 002390's price volatile compared to industry and market?
002390 volatility
002390 Average Weekly Movement6.6%
Pharmaceuticals Industry Average Movement7.4%
Market Average Movement8.6%
10% most volatile stocks in CN Market12.8%
10% least volatile stocks in CN Market5.7%

Stable Share Price: 002390 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 002390's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19955,149Lingzhong Kongwww.xinbang.com

Guizhou Xinbang Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells Chinese herbal medicines and other pharmaceutical products in China and internationally. The company offers cardiovascular and cerebrovascular, digestive system, endocrine, tumor and immune regulation, blood system, rheumatism and rheumatoid, urinary system, antipyretic analgesic, cold medicine, gynecological treatment, and anti-infective drugs. It also operates in medical services; and pharmaceutical circulation business.

Guizhou Xinbang Pharmaceutical Co., Ltd. Fundamentals Summary

How do Guizhou Xinbang Pharmaceutical's earnings and revenue compare to its market cap?
002390 fundamental statistics
Market capCN¥8.31b
Earnings (TTM)CN¥217.25m
Revenue (TTM)CN¥6.20b

38.0x

P/E Ratio

1.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
002390 income statement (TTM)
RevenueCN¥6.20b
Cost of RevenueCN¥5.10b
Gross ProfitCN¥1.10b
Other ExpensesCN¥882.31m
EarningsCN¥217.25m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.11
Gross Margin17.73%
Net Profit Margin3.50%
Debt/Equity Ratio8.6%

How did 002390 perform over the long term?

See historical performance and comparison

Dividends

1.4%

Current Dividend Yield

78%

Payout Ratio